Company Announcements In March, Qlucore partnered with TATAA Biocenter, which will use Qlucore’s Omics Explorer Software for providing NGS data analysis and for training courses. Illumina formed a collaboration with Merck Serono to develop a universal NGS-based oncology diagnostic. The assays will be used to detect and measure multiple variants simultaneously to support clinical trials. […]
The Life Science Sales Index article in the March 15 issue of IBO excluded a summary of Tecan results. For the second half of 2014, Tecan sales grew 10.2%, 5.8% organically, to CHF 227.5 million ($242.0 million = CHF 0.94 = $1). The acquisition of IBL (see IBO 7/31/14) contributed 4.5% to sales growth. Currency […]
The Korea National Food Cluster, or Foodopolis, will be built in Iksan, South Korea, and open by June 2016. It will be the site of R&D for about 150 food companies. The center is expected to create 22,000 jobs and generate $14 billion in processed and value-added products each year. Three R&D facilities are planned: […]
This month, Canada released its Economic Action Plan 2015. Starting in 2017, the Canada Foundation for Innovation will receive CAD 1.33 billion ($1.09 billion) over six years for research infrastructure at hospitals and universities. Over six years, federal labs and research facilities will get CAD 380 million for repairs and upgrades. Beginning in 2016, the […]
International backing of about $4.5 million will enable the formation of the Alliance for Accelerating Excellence in Science in Africa (AESA), planned for June. The Alliance will direct African science programs and manage research focusing on the continent. Much of the research funding in Africa is from international funders, which determine how it is spent. […]
The US FDA has finalized its 2012 drafts on biosimilarity with three guidance documents. The first guidance presents the approach for sponsors to obtain evidence showing biosimilarity and by the FDA in reviewing applications for biosimilars. It also provides some clarifications in its recommendations. It encourages frequent consultation with the FDA during the early stages […]
In the 20 or so years prior to 2000, forensic analysis of hair was used against defendants in about 2,500 US trials. Reviews of 342 of these cases by the US Justice Department and the FBI revealed that in 257 of 268 of these cases, 26 of 28 FBI examiners gave flawed testimony, overstating matches […]
More than 60 authors from the academic and industrial sectors have published a science and technology road map in the journal Nanoscale for graphene, related to 2-D crystals, other 2-D materials and hybrids. The authors are members of the Graphene Flagship, an international research initiative formed to take graphene from labs and into European society […]
In this article, IBO updates the patent litigation landscape for the analytical instrument and lab product industry. New Development In March, the US Court of Appeals for the Federal Circuit reversed in part and vacated in part the judgment in favor of Enzo Biochem and Yale University in their patent infringement suit against Life Technologies […]
US equity markets traded at record levels in April due to stronger-than-expected corporate earnings and additional monetary policy easing in China. However, weak US manufacturing, durable goods orders and GDP data caused equity markets to retract toward the end of the month. US economic growth nearly stalled in the first quarter, expanding at a modest […]
Pay Invoice
Latest Blogs
-
MOBILion Expands into Proteomics MS Market
April 30, 2026 5:05 pm
-
Carterra Introduces Faster SPR
March 27, 2026 7:26 pm
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
